Trial Profile
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2018
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Therapeutic Use
- Sponsors Pierre Fabre
- 14 Nov 2018 The trial has been completed in France.
- 28 Jun 2012 Planned end date changed from 18 Jun 2011 to 18 Mar 2012 as reported by European Clinical Trials Database record.
- 16 Jun 2011 New trial record